Amount of eligible patients: CDEC reviewed the uncertainty in the number of people with moderately critical to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some individuals that are labeled as having gentle or moderate disease might have a significant bleeding phenotype, https://raymondegffd.livebloggs.com/42461626/examine-this-report-on-hemgenix